Imaging of Thyroid Cancer

Seminars in Ultrasound, CT and MRI

Volumn 33, Issue 2, 2012, Pages 138-149

  Aiken, Ashley H ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; SOMATOSTATIN DERIVATIVE; THYROID HORMONE; THYROTROPIN;

AGE DISTRIBUTION; ANAPLASTIC THYROID CARCINOMA; ARTICLE; ASPIRATION BIOPSY; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CROSS-SECTIONAL STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIFFERENTIATED THYROID CANCER; ECHOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; HURTHLE CELL CARCINOMA; IMAGE ANALYSIS; MEDULLARY CARCINOMA; METASTASIS POTENTIAL; MICROSCOPY; MORBIDITY; ONCOCYTOMA; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; POORLY DIFFERENTIATED THYROID CANCER; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; REOPERATION; SEX DIFFERENCE; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID LYMPHOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; WHOLE BODY IMAGING;

CARCINOMA; DIAGNOSTIC IMAGING; HUMANS; LYMPHOMA; THYROID NEOPLASMS;

EID: 84858121337     PISSN: 08872171     EISSN: 15585034     Source Type: Journal    
DOI: 10.1053/j.sult.2011.12.006     Document Type: Article

References (44)

1. Facts and figures 2007 2007, American Cancer Society, Paper presented at: American Cancer Society, Atlanta, GA.
2. Davidson B.J., Burman K.D. Cancer of the thyroid and parathyroid. Head and Neck Cancer 2009, 690-731. Lippincott Williams & Wilkins, Philadelphia. 3rd ed. L.B. Harrison, R.B. Sessions, W.K. Hong (Eds.).
3. Fukunaga F.H., Yatani R. Geographic pathology of occult thyroid carcinomas. Cancer 1975, 36:1095-1099.
4. Grebe S.K., Hay I.D. Thyroid cancer nodal metastases: Biologic significance and therapeutic considerations. Surg Oncol Clin N Am 1996, 5:43-63.
5. Scheumann G.F., Gimm O., Wegener G., et al. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg 1994, 18:559-567. discussion:567-558.
6. Ito Y., Uruno T., Nakano K., et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 2003, 13:381-387.
7. Chow S.M., Law S.C., Chan J.K., et al. Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality. Cancer 2003, 98:31-40.
8. Qubain S.W., Nakano S., Baba M., et al. Distribution of lymph node micrometastasis in pN0 well-differentiated thyroid carcinoma. Surgery 2002, 131:249-256.
9. Arturi F., Russo D., Giuffrida D., et al. Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes. J Clin Endocrinol Metab 1997, 82:1638-1641.
10. Hundahl S.A., Fleming I.D., Fremgen A.M., et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998, 83:2638-2648. [see comments].
11. Carcangiu M.L., Bianchi S. Diffuse sclerosing variant of papillary thyroid carcinoma. Clinicopathologic study of 15 cases. Am J Surg Pathol 1989, 13:1041-1049.
12. Falvo L., Giacomelli L., D'Andrea V., et al. Prognostic importance of sclerosing variant in papillary thyroid carcinoma. Am Surg 2006, 72:438-444.
13. Johnson T.L., Lloyd R.V., Thompson N.W., et al. Prognostic implications of the tall cell variant of papillary thyroid carcinoma. Am J Surg Pathol 1988, 12:22-27.
14. Greenfield L., Luk K. Thyroid. Principles and Practice of Radiation Oncology 1992, 1356-1380. Lippincott, Philadelphia. C. Perez, L. Brady (Eds.).
15. LiVolsi V. Papillary lesions of the thyroid, in Surgical Pathology of the Thyroid 1990, 136. W. B. Saunders, Philadelphia.
16. Beasley N.J., Lee J., Eski S., et al. Impact of nodal metastases on prognosis in patients with well-differentiated thyroid cancer. Arch Otolaryngol Head Neck Surg 2002, 128:825-828.
17. Hall F.T., Freeman J.L., Asa S.L., et al. Intratumoral lymphatics and lymph node metastases in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg 2003, 129:716-719.
18. Mazzaferri E.L., Jhiang S.M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994, 97:418-428.
19. Hughes C.J., Shaha A.R., Shah J.P., et al. Impact of lymph node metastasis in differentiated carcinoma of the thyroid: A matched-pair analysis. Head Neck 1996, 18:127-132.
20. Akslen L.A., Haldorsen T., Thoresen S.O., et al. Survival and causes of death in thyroid cancer: A population-based study of 2479 cases from Norway. Cancer Res 1991, 51:1234-1241.
21. Shaha A.R., Shah J.P., Loree T.R. Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid. Am J Surg 1996, 172:692-694.
22. Kushchayeva Y., Duh Q.Y., Kebebew E., et al. Comparison of clinical characteristics at diagnosis and during follow-up in 118 patients with Hurthle cell or follicular thyroid cancer. Am J Surg 2008, 195:457-462.
23. Stojadinovic A., Hoos A., Ghossein R.A., et al. Hurthle cell carcinoma: A 60-year experience. Ann Surg Oncol 2002, 9:197-203.
24. Sherman S.I., Angelos P., Ball D.W., et al. Thyroid carcinoma. J Natl Compr Canc Netw 2007, 5:568-621.
25. Modigliani E., Cohen R., Campos J.M., et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: Results in 899 patients. The GETC Study Group. Groupe d'etude des tumeurs a calcitonine. Clin Endocrinol (Oxf) 1998, 48:265-273.
26. Patel K.N., Shaha A.R. Poorly differentiated and anaplastic thyroid cancer. Cancer Control 2006, 13:119-128.
27. Jiang J.Y., Tseng F.Y. Prognostic factors of anaplastic thyroid carcinoma. J Endocrinol Invest 2006, 29:11-17.
28. Kebebew E., Greenspan F.S., Clark O.H., et al. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 2005, 103:1330-1335.
29. Hyman G.A., Wolff M. Malignant lymphomas of the salivary glands. Review of the literature and report of 33 new cases, including four cases associated with the lymphoepithelial lesion. Am J Clin Pathol 1976, 65:421-438.
30. Aiken A.H., Glastonbury C. Imaging Hodgkin and non-Hodgkin lymphoma in the head and neck. Radiol Clin North Am 2008, 46:363-378. ix-x.
31. Widder S., Pasieka J.L. Primary thyroid lymphomas. Curr Treat Options Oncol 2004, 5:307-313.
32. Weber A.L., Randolph G., Aksoy F.G. The thyroid and parathyroid glands. CT and MR imaging and correlation with pathology and clinical findings. Radiol Clin North Am 2000, 38:1105-1129.
33. Cooper D.S., Doherty G.M., Haugen B.R., et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009, 19:1167-1214.
34. Loevner L.A., Kaplan S.L., Cunnane M.E., et al. Cross-sectional imaging of the thyroid gland. Neuroimaging Clin N Am 2008, 18:445-461. vii.
35. Kuna S.K., Bracic I., Tesic V., et al. Ultrasonographic differentiation of benign from malignant neck lymphadenopathy in thyroid cancer. J Ultrasound Med 2006, 25:1531-1537. quiz:1538-1540.
36. Leboulleux S., Girard E., Rose M., et al. Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer. J Clin Endocrinol Metab 2007, 92:3590-3594.
37. Frasoldati A., Valcavi R. Challenges in neck ultrasonography: Lymphadenopathy and parathyroid glands. Endocr Pract 2004, 10:261-268.
38. Som P.M., Brandwein M., Lidov M., et al. The varied presentations of papillary thyroid carcinoma cervical nodal disease: CT and MR findings. AJNR Am J Neuroradiol 1994, 15:1123-1128.
39. Takashima S., Sone S., Takayama F., et al. Papillary thyroid carcinoma: MR diagnosis of lymph node metastasis. AJNR Am J Neuroradiol 1998, 19:509-513.
40. Dietlein M., Scheidhauer K., Voth E., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997, 24:1342-1348.
41. Feine U., Lietzenmayer R., Hanke J.P., et al. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996, 37:1468-1472.
42. Abraham T., Schoder H. Thyroid cancer-Indications and opportunities for positron emission tomography/computed tomography imaging. Semin Nucl Med 2011, 41:121-138.
43. Wang W., Macapinlac H., Larson S.M., et al. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999, 84:2291-2302.
44. Chung J.K., So Y., Lee J.S., et al. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. J Nucl Med 1999, 40:986-992.